5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow Optimized Background Regimen (OBR): new trials by email Literature Review of Optimized Background Regimen (OBR) trials Research Report on Optimized Background Regimen (OBR)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR) - HIV-1-infection | Phase 2 | Recruiting | Gilead Sciences | 12 | 2025-03-26 | 2026-04-24 |
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir - HIV-1-infection | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 72 | 2019-11-21 | 2026-10-01 |
| Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV ibalizumab, Optimized Background Regimen (OBR) - HIV | Phase 3 | Completed | TaiMed Biologics Inc. | 40 | 2015-08-01 | 2020-03-19 |
| Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Levofloxacin, Optimized background regimen (OBR) - Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Boston University | 111 | 2015-01-01 | 2023-05-24 |
| A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) Delamanid, Delamanid Pediatric Formulation (DPF), Optimized Background Regimen (OBR) - Multidrug Resistant Tuberculosis | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 37 | 2013-07-20 | 2020-11-23 |
| Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis Delamanid, Optimized Background Regimen (OBR) - Tuberculosis | Phase 2 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | 2010-02-19 | 2021-11-11 |
| TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents Etravirine (TMC125), Optimized background regimen (OBR) - HIV-1 | Phase 2 | Completed | Tibotec Pharmaceuticals, Ireland | 103 | 2008-11-01 | 2015-04-23 |
| A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Delamanid, Optimized Background Regimen (OBR), Placebo - Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 481 | 2008-05-08 | 2021-12-01 |
| SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC tipranavir, ritonavir, Optimized Background Regimen (OBR) - HIV Infections | Phase 3 | Terminated | Boehringer Ingelheim | 33 | 2007-02-01 | 2014-06-27 |
Tuberculosis, Multidrug-Resistant (4) · Tuberculosis (3) · Bacterial Infections (1) · Extensively Drug-Resistant Tuberculosis (1) · HIV Infections (1) · Mycobacterium Infections (1) · Tuberculosis, Pulmonary (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Gilead Sciences (2) · Boehringer Ingelheim (1) · Boston University (1) · TaiMed Biologics Inc. (1) · Tibotec Pharmaceuticals, Ireland (1)
United States (6) · South Africa (5) · Canada (3) · Spain (3) · Argentina (2) · Brazil (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Latvia (2) · Peru (2) · Philippines (2) · Puerto Rico (2) · Taiwan (2)
Anjanette Reyes-De Leon, MD (1) · Charles R Horsburgh, MD (1) · Louvina van der Laan, MD (1) · Melchor VG Frias, IV, MD (1)
PMID 22670901, PMID 26566161, PMID 29178937, PMID 30012767, PMID 30110589, PMID 30373800, PMID 35404075, PMID 35996282, PMID 40080768
2009 (1), 2019 (1), U01AI100805 (1)